185 related articles for article (PubMed ID: 15049639)
1. Indium-mediated atom-transfer and reductive radical cyclizations of iodoalkynes: synthesis and biological evaluation of HIV-protease inhibitors.
Yanada R; Koh Y; Nishimori N; Matsumura A; Obika S; Mitsuya H; Fujii N; Takemoto Y
J Org Chem; 2004 Apr; 69(7):2417-22. PubMed ID: 15049639
[TBL] [Abstract][Full Text] [Related]
2. Reduction of peptide character of HIV protease inhibitors that exhibit nanomolar potency against multidrug resistant HIV-1 strains.
Tamamura H; Koh Y; Ueda S; Sasaki Y; Yamasaki T; Aoki M; Maeda K; Watai Y; Arikuni H; Otaka A; Mitsuya H; Fujii N
J Med Chem; 2003 Apr; 46(9):1764-8. PubMed ID: 12699395
[TBL] [Abstract][Full Text] [Related]
3. Stereocontrolled synthesis and biological activity of two diastereoisomers of the potent HIV-1 protease inhibitor saquinavir.
Righi G; Ciambrone S; Bonini C; Campaner P
Bioorg Med Chem; 2008 Jan; 16(2):902-8. PubMed ID: 17964171
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 protease inhibitors with a transition-state mimic comprising a tertiary alcohol: improved antiviral activity in cells.
Mahalingam AK; Axelsson L; Ekegren JK; Wannberg J; Kihlström J; Unge T; Wallberg H; Samuelsson B; Larhed M; Hallberg A
J Med Chem; 2010 Jan; 53(2):607-15. PubMed ID: 19961222
[TBL] [Abstract][Full Text] [Related]
6. Solid-phase synthesis of HTLV-1 protease inhibitors containing hydroxyethylamine dipeptide isostere.
Akaji K; Teruya K; Aimoto S
J Org Chem; 2003 Jun; 68(12):4755-63. PubMed ID: 12790579
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
Narendra Babu SN; Rangappa KS
Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
De Lucca GV; Liang J; Aldrich PE; Calabrese J; Cordova B; Klabe RM; Rayner MM; Chang CH
J Med Chem; 1997 May; 40(11):1707-9. PubMed ID: 9171880
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.
Zhao C; Sham HL; Sun M; Stoll VS; Stewart KD; Lin S; Mo H; Vasavanonda S; Saldivar A; Park C; McDonald EJ; Marsh KC; Klein LL; Kempf DJ; Norbeck DW
Bioorg Med Chem Lett; 2005 Dec; 15(24):5499-503. PubMed ID: 16203141
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus.
Raghavan S; Lu Z; Beeson T; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Gabryelski L; Emini E; Tata JR
Bioorg Med Chem Lett; 2007 Oct; 17(19):5432-6. PubMed ID: 17692518
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
Raza A; Sham YY; Vince R
Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
[TBL] [Abstract][Full Text] [Related]
12. Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles.
Miller JF; Brieger M; Furfine ES; Hazen RJ; Kaldor I; Reynolds D; Sherrill RG; Spaltenstein A
Bioorg Med Chem Lett; 2005 Aug; 15(15):3496-500. PubMed ID: 15990305
[TBL] [Abstract][Full Text] [Related]
13. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
[TBL] [Abstract][Full Text] [Related]
14. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of the HIV-1 protease incorporating cyclic urea P1-P2 scaffold.
Kazmierski WM; Furfine E; Gray-Nunez Y; Spaltenstein A; Wright L
Bioorg Med Chem Lett; 2004 Nov; 14(22):5685-7. PubMed ID: 15482948
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel cyclic urea based HIV-1 protease inhibitors.
Nugiel DA; Reese K
Drug Des Discov; 1995 Nov; 13(2):83-7. PubMed ID: 8872453
[TBL] [Abstract][Full Text] [Related]
18. Discovery of imidazolidine-2,4-dione-linked HIV protease inhibitors with activity against lopinavir-resistant mutant HIV.
Flosi WJ; DeGoey DA; Grampovnik DJ; Chen HJ; Klein LL; Dekhtyar T; Masse S; Marsh KC; Mo HM; Kempf D
Bioorg Med Chem; 2006 Oct; 14(19):6695-712. PubMed ID: 16828558
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]